From BusinessWire Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced its support for the ReSolve study, an ongoing natural history study designed… Read More »
Dyne Therapeutics to support ReSolve study of FSHD
Disappointing news from Acceleron
From Acceleron’s press release Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment… Read More »
FSHD Society signs agreement to expand CTRN
From PRWeb The FSHD Society announced today that it has signed a memorandum of understanding to enter into a three-year agreement to enable the expansion of the international facioscapulohumeral muscular dystrophy… Read More »
Charis Himeda talks about CRISPR and FSHD
From the FSHD Society’s webinar series on facioscapulohumeral muscular dystrophy. Charis Himeda, PhD, of the University of Nevada Reno, discusses her groundbreaking work showing how CRISPR “gene editing” technology can… Read More »
Fulcrum Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
August 19, 2019 at 7:00 AM EDT From Fulcrum press release. PDF Version CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving… Read More »